Tahoora Ghasemzadeh, Maliheh Hasannia, Khalil Abnous, Seyed Mohammad Taghdisi, Sirous Nekooei, Negar Nekooei, Mohammad Ramezani, Mona Alibolandi
{"title":"Preparation of targeted theranostic red blood cell membranes-based nanobubbles for treatment of colon adenocarcinoma.","authors":"Tahoora Ghasemzadeh, Maliheh Hasannia, Khalil Abnous, Seyed Mohammad Taghdisi, Sirous Nekooei, Negar Nekooei, Mohammad Ramezani, Mona Alibolandi","doi":"10.1080/17425247.2022.2152792","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Designing and fabrication of theranostic systems based on nanoscale gaseous vesicular systems, named nanobubbles (NBs), attracted enormous interest in recent years. Biomimetic vesicular platform (V-RBC-M) can improve the pharmacokinetics of the prepared platform due to augmented circulation half-life, desirable biodegradability and biocompatibility and reduced immunogenicity.</p><p><strong>Methods: </strong>V-RBC-M were used for the encapsulation of lipophilic camptothecin (CPT) in the bilayer of vesicles through top-down method, followed by filling the core of V-RBC-M with inert SF6 gas to fabricate NBs with ultrasonic contrast enhancement capability (SF6-NB-CPT). In the next step, targeted NBs were formed <i>via</i> decoration of MUC1 aptamer on the surface of NBs (Apt-SF6-NB-CPT).</p><p><strong>Results: </strong>The designed bio-NBs indicated high encapsulation efficiency and the sustained release of CPT at pH 7.4. <i>In vitro</i> study demonstrated higher cellular uptake and cytotoxicity of Apt-SF6-NB-CPT compared to SF6-NB-CPT in MUC1-overexpressing cells (C26). <i>In vivo</i> antitumor efficacy of the prepared NBs on C26 bearing BALB/c mice showed greater therapeutic efficacy and survival rate for Apt-SF6-NB-CPT. In this regard, SF6-NB-CPT showed 58% tumor growth suppression while Apt-SF6-NB-CPT system provided 95% tumor growth suppression. Furthermore, echogenic capability of SF6-NB-CPT was demonstrated through <i>in vitro</i> and <i>in vivo</i> ultrasonic imaging.</p><p><strong>Conclusions: </strong>Our finding demonstrated that the prepared targeted NBs are a promising theranostic platform with effective therapeutic and diagnotic potentials.</p>","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":"20 1","pages":"131-143"},"PeriodicalIF":5.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425247.2022.2152792","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
Abstract
Objectives: Designing and fabrication of theranostic systems based on nanoscale gaseous vesicular systems, named nanobubbles (NBs), attracted enormous interest in recent years. Biomimetic vesicular platform (V-RBC-M) can improve the pharmacokinetics of the prepared platform due to augmented circulation half-life, desirable biodegradability and biocompatibility and reduced immunogenicity.
Methods: V-RBC-M were used for the encapsulation of lipophilic camptothecin (CPT) in the bilayer of vesicles through top-down method, followed by filling the core of V-RBC-M with inert SF6 gas to fabricate NBs with ultrasonic contrast enhancement capability (SF6-NB-CPT). In the next step, targeted NBs were formed via decoration of MUC1 aptamer on the surface of NBs (Apt-SF6-NB-CPT).
Results: The designed bio-NBs indicated high encapsulation efficiency and the sustained release of CPT at pH 7.4. In vitro study demonstrated higher cellular uptake and cytotoxicity of Apt-SF6-NB-CPT compared to SF6-NB-CPT in MUC1-overexpressing cells (C26). In vivo antitumor efficacy of the prepared NBs on C26 bearing BALB/c mice showed greater therapeutic efficacy and survival rate for Apt-SF6-NB-CPT. In this regard, SF6-NB-CPT showed 58% tumor growth suppression while Apt-SF6-NB-CPT system provided 95% tumor growth suppression. Furthermore, echogenic capability of SF6-NB-CPT was demonstrated through in vitro and in vivo ultrasonic imaging.
Conclusions: Our finding demonstrated that the prepared targeted NBs are a promising theranostic platform with effective therapeutic and diagnotic potentials.
目的:基于纳米级气体囊泡系统的治疗系统的设计和制造近年来引起了人们的极大兴趣。仿生囊泡平台(V-RBC-M)由于增加了循环半衰期、良好的生物降解性和生物相容性以及降低了免疫原性,可以改善制备的平台的药代动力学。方法:采用自顶向下的方法将亲脂喜树碱(CPT)包埋在囊泡双层中,然后在V-RBC-M的核心填充惰性SF6气体,制备具有超声对比增强能力的nb (SF6- nb -CPT)。下一步,通过在NBs表面修饰MUC1适体(Apt-SF6-NB-CPT)形成靶向NBs。结果:所设计的生物nbs包封效率高,CPT在pH 7.4下缓释。体外研究表明,在muc1过表达细胞中,与SF6-NB-CPT相比,Apt-SF6-NB-CPT的细胞摄取和细胞毒性更高(C26)。制备的NBs对携带C26的BALB/c小鼠的体内抗肿瘤效果显示,对Apt-SF6-NB-CPT具有更高的治疗效果和生存率。SF6-NB-CPT系统对肿瘤生长的抑制作用为58%,而Apt-SF6-NB-CPT系统对肿瘤生长的抑制作用为95%。此外,SF6-NB-CPT通过体外和体内超声成像验证了其超声成像能力。结论:我们的研究结果表明,制备的靶向NBs是一个有希望的治疗平台,具有有效的治疗和诊断潜力。
期刊介绍:
Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.